Document Detail


Bevacizumab (avastin) for the treatment of retinopathy of prematurity.
MedLine Citation:
PMID:  22763251     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Authors:
Michele J Beaulieu
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Neonatal network : NN     Volume:  31     ISSN:  1539-2880     ISO Abbreviation:  Neonatal Netw     Publication Date:    2012 Jul-Aug
Date Detail:
Created Date:  2012-07-05     Completed Date:  2012-11-19     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  8503921     Medline TA:  Neonatal Netw     Country:  United States    
Other Details:
Languages:  eng     Pagination:  242-7     Citation Subset:  N    
Affiliation:
All Children’s Hospital. nnpdoctor@gmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiogenesis Inhibitors / pharmacokinetics,  pharmacology,  therapeutic use*
Antibodies, Monoclonal, Humanized / pharmacokinetics,  pharmacology,  therapeutic use*
Biological Markers / metabolism
Dose-Response Relationship, Drug
Drug Administration Schedule
Humans
Infant, Newborn
Infant, Premature
Neovascularization, Physiologic / drug effects
Retinopathy of Prematurity / drug therapy*,  metabolism,  physiopathology
Vascular Endothelial Growth Factor A / antagonists & inhibitors,  metabolism
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 0/Biological Markers; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Neonatal mythbusters: evaluating the evidence for and against pharmacologic and nonpharmacologic man...
Next Document:  Information literacy: using computers to connect practice to evidence.